Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma.
Authors
Li-Yuan Bai
China Medical University Hospital, China Medical University, Taichung, Taiwan
Li-Yuan Bai , Chung-Pin Li , Yan-Shen Shan , Shih-Chang Chuang , Jen-Shi Chen , Nai-Jung Chiang , Yen-Yang Chen , Hsiao-Hui Tsou , Mei-Hsing Chuang , Chang-Fang Chiu , Tsang-Wu Liu , Li-Tzong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03559348
DOI
10.1200/JCO.2022.40.4_suppl.550
Abstract #
550
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
First Author: Jaime Feliu Batlle
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang
Poster
2020 ASCO Virtual Scientific Program
EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).
First Author: Li-Tzong Chen